Tag Archives: Its Private Valuation

The Daily Startup: NovoCure IPO Misses Its Private Valuation

Medical-technology company NovoCure Ltd.NVCR -5.58% marks the latest company to price its initial public offering below its last private round, underscoring a disconnect between private valuations and what IPO investors are willing to pay. NovoCure  makes a device to treat a form of brain cancer. It launched on the Nasdaq NDAQ -0.10% on Friday, opening at $20.15 after selling 7.5 million shares at $22 ... Read More »